---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-157992"
form_type: "8-K"
ticker: null
cik: "0001850079"
company_name: "Telesis Bio Inc."
filed_at: "2023-05-31T23:59:59+00:00"
generated_at: "2026-06-14T10:49:16.082358+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Telesis Bio raises $28M via convertible preferred, cuts 2023 revenue guidance to ~$35M

## Summary
- Gross proceeds of $28.0M from redeemable convertible preferred; warrants could add $46.2M if cash exercised.
- 2023 revenue guidance lowered to approximately $35M; operating expenses ~$55M; gross margin 57% unchanged.
- CEO states goal to approach profitability in 2024 timeframe; financing led by Novalis LifeSciences.
- Paul Meister of Novalis appointed to board of directors, expanding board from seven to eight.
- Private placement expected to close June 2, 2023; investors include Northpond, BroadOak, and CEO affiliate M-185.

## SEC filing metadata
- accession: 0001193125-23-157992
- form_type: 8-K
- cik: 0001850079
- company_name: Telesis Bio Inc.
- filed_at: 2023-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.03, 3.02, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/0001193125-23-157992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/d514788d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-157992
- JSON: https://secwatch.observer/filing/0001193125-23-157992.json
- Plain text: https://secwatch.observer/filing/0001193125-23-157992.txt

## Key facts
- Executive change
  Paul Meister was appointed as Director at Telesis Bio Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Paul Meister, a partner at Novalis LifeSciences LLC, as a director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/0001193125-23-157992-index.htm
- Governance Changes
  Telesis Bio Inc.: Filed Certificate of Designation to establish Redeemable Convertible Preferred Stock with rights, preferences, and privileges.
  - Change: charter amendment
  source text: The Company expects to file with the Secretary of State of the State of Delaware the Certificate of Designation attached hereto as Exhibit 3.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/0001193125-23-157992-index.htm
- Material Agreements
  Telesis Bio Inc. entered into Preferred Stock and Warrant Purchase Agreement with Novalis LifeSciences Investments II, L.P. and certain other investors valued at approximately $28.0 million (effective 2023-05-31).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Novalis LifeSciences Investments II, L.P. and certain other investors
  - Value: approximately $28.0 million
  - Effective: 2023-05-31
  source text: On May 31, 2023, Telesis Bio Inc. (the “Company”) entered into a redeemable convertible preferred stock and warrant purchase agreement (the “Preferred Stock and Warrant Purchase Agreement”) with Novalis LifeSciences Investments II, L.P. (the “Lead Investor”) and certain other investors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/0001193125-23-157992-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.